rs370609227
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM5BP4BS2
The NM_003919.3(SGCE):c.391A>G(p.Ile131Val) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000177 in 1,590,418 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/23 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I131K) has been classified as Pathogenic.
Frequency
Consequence
NM_003919.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SGCE | NM_003919.3 | c.391A>G | p.Ile131Val | missense_variant, splice_region_variant | 4/11 | ENST00000648936.2 | NP_003910.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SGCE | ENST00000648936.2 | c.391A>G | p.Ile131Val | missense_variant, splice_region_variant | 4/11 | NM_003919.3 | ENSP00000497130 | A1 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152178Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000182 AC: 45AN: 247766Hom.: 0 AF XY: 0.000172 AC XY: 23AN XY: 134066
GnomAD4 exome AF: 0.000181 AC: 261AN: 1438240Hom.: 1 Cov.: 25 AF XY: 0.000172 AC XY: 123AN XY: 716710
GnomAD4 genome AF: 0.000138 AC: 21AN: 152178Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74342
ClinVar
Submissions by phenotype
not provided Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 10, 2016 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Myoclonic dystonia 11 Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 16, 2024 | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 131 of the SGCE protein (p.Ile131Val). This variant is present in population databases (rs370609227, gnomAD 0.04%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with SGCE-related conditions. ClinVar contains an entry for this variant (Variation ID: 374642). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 03, 2021 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 17, 2024 | Variant summary: SGCE c.391A>G (p.Ile131Val) results in a conservative amino acid change located in the dystroglycan-type cadherin-like domain (IPR006644) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant is located near a canonical splice site and therefore may affect splicing. Several computational tools predict a significant impact on normal splicing: Three predict the variant creates a 5' donor site. Two predict the variant strengthens a 3' acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00018 in 247766 control chromosomes, predominantly at a frequency of 0.00037 within the Non-Finnish European subpopulation in the gnomAD database. This frequency is higher than would be expected for a rare autosomal dominant disorder, suggesting the variant may be benign. However it should be noted that in SGCE-related Myoclonic Dystonia, penetrance is determined by parental origin of the altered allele due to maternal imprinting, therefore a pathogenic variant on the maternally-derived SGCE allele typically does not result in the disease phenotype (Raymond_2003, Gene Reviews), making it difficult to interpret whether the frequency of the c.391A>G variant in the control population allows for any conclusion about variant significance. To our knowledge, no occurrence of c.391A>G in individuals affected with Myoclonic Dystonia 11 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 374642). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 10, 2023 | The c.391A>G (p.I131V) alteration is located in exon 4 (coding exon 4) of the SGCE gene. This alteration results from a A to G substitution at nucleotide position 391, causing the isoleucine (I) at amino acid position 131 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at